Clinicopathologic significance of plasma matrix metalloproteinase-2 and -9 levels in patients with undifferentiated nasopharyngeal carcinoma
- 1 June 2004
- journal article
- research article
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 30 (5) , 560-564
- https://doi.org/10.1016/j.ejso.2004.02.007
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Expression of matrix metalloproteinase 1, matrix metalloproteinase 2, and matrix metalloproteinase 9 in carcinoma of the head and neckCancer, 2002
- Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancerAnnals of Oncology, 2002
- Nasopharyngeal carcinomaAnnals of Oncology, 2002
- Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targetsInternational Journal of Cancer, 2002
- Enhanced Production of Matrix Metalloproteinase-2 in Human Head and Neck Carcinomas is Correlated with Lymph Node MetastasisActa Oto-Laryngologica, 2002
- Serum levels of matrix metalloproteinase 2 in patients with breast cancerCancer Letters, 2001
- Increased Extracellular Matrix Remodeling Is Associated With Tumor Progression in Human Hepatocellular CarcinomasHepatology, 2001
- Expression of matrix metalloproteinases and the tissue inhibitors of metalloproteinases and their local invasiveness and metastasis in Chinese human pancreatic cancerJournal of Surgical Oncology, 2000
- Elevated Plasma Levels of Matrix Metalloproteinase–9 (92–Kd Type Iv Collagenase/Gelatinase B) in Hepatocellular CarcinomaHepatology, 1996
- A matrix metalloproteinase expressed on the surface of invasive tumour cellsNature, 1994